• About the Quintiles Experts

    • Erica Caveney, M.D.

      Senior Director, Medical- Global Therapeutic Strategic Lead of Diabetes at Quintiles

      As Quintiles’ Global Therapeutic Strategic Lead of Diabetes, Dr. Caveney chairs Quintiles’ Diabetes Center of Excellence. Dr. Caveney is Board Certified in internal medicine and endocrinology, diabetes, and metabolism. Most recently, she led the physician team within Quintiles’ Cardiovascular and Metabolic Delivery Group as well as the Cardiovascular Outcome Center of Excellence.

      Her areas of interest include: type 1 and type 2 diabetes mellitus, obesity, metabolic syndrome, and cardiovascular outcomes studies. She has authored many peer-reviewed articles on diabetes and obesity, including articles on diabetes biomarkers, cardiovascular outcomes studies in anti-diabetes drugs, and a review of obesity drugs.

      Dr. Caveney completed medical school at the West Virginia University School of Medicine and her internship and residency in internal medicine at West Virginia University Hospitals. She completed her endocrinology fellowship at the University of North Carolina Hospitals. She joined Quintiles in 2007 from Duke University Medical Center where she was on faculty in the Endocrinology, Metabolism, and Nutrition division.

    • Mala Puri, M.D.

      Associate Director, Medical and Scientific Services in the Metabolic and Cardiovascular Therapeutic Delivery Unit at Quintiles

      Dr. Mala Puri, M.D. is the Associate Director of Medical and Scientific Services in the Metabolic and Cardiovascular Therapeutic Delivery Unit of Quintiles. She is a board certified pediatric endocrinologist with approximately 10 years of experience in the treatment of childhood diabetes, obesity and endocrine disorders. Prior to joining Quintiles, she conducted several studies relating to obese minority adolescents, looking specifically at childhood type 2 diabetes and the metabolic syndrome.

      Dr. Puri earned her Bachelor of Arts degree in Biology from The Johns Hopkins University and her medical degree from the University of Oklahoma College of Medicine. She completed both her pediatric residency and a fellowship in endocrinology at Albert Einstein College of Medicine, Montefiore Medical Center in Bronx, NY. After completing her training, she joined the faculty at the University of North Carolina in Chapel Hill, where she served as co-director of the pediatric diabetes program.

    • Nicole Connelly, Ph.D.

      Principal Consultant, Drug Development Consulting, at Quintiles

      Dr. Nicole Connelly has 10 years of strategy consulting experience focusing on pharmaceutical R&D, market access strategies and organizational alignment to meet fundamental business goals. She has contributed to and led cross-functional teams on projects ranging from developing strategies that improve speed to market for clinical assets to driving corporate strategies that address evolving environmental pressures.

      At Quintiles, Dr. Connelly focuses on clinical partnership optimization, development of business processes to translate clinical strategies to clinical plans, oncology and diabetes value proposition, and pricing and reimbursement strategies. Dr. Connelly regularly engages across Quintiles to drive cross-functional processes for operationalizing clinically and commercially integrated asset strategies and development plans. Dr. Connelly earned he Ph.D. in Microbiology from Duke University.

    For more information, please visit our Diabetes Patient Facebook Community.

  • Video Series | Quintiles' Perspectives on Diabetes

    Erica Caveney, M.D. and Nicole Connelly, Ph.D. provide expert insights on:

    • Global Impact of Diabetes
    • The Changing Landscape of Diabetes
    • The R&D Pipeline
    • The Future of Diabetes

    Download White Paper | Diabetes Drug Development: A Perspective on Pediatric Indication Planning

    View Larger

    Download | IDF Diabetes Atlas

    View Webinar | Improve Protocol Designs for Diabetes Trials Using Predictive Techniques

    View Larger

    View Larger

    View Webinar | Diabetes Product Value: Stakeholders' Changing Expectations and the Role of Real World Evidence

    View Webinar | Best Practices in Patient Recruitment and Retention for Diabetes Trials

    View Larger

    Download Case Study | Improving Adherence: Certified Diabetes Educators Reach Over 345,000 Diabetes Patients

    View Webinar | Diabetes Drug Development: A Perspective on Pediatric Indication Planning

    Forward-Looking Statements
    This site and its related links, including videos, and other content may contain forward-looking statements that reflect, among other things, Quintiles' current thinking, expectations and ideas, all of which are subject to known and unknown risks, uncertainties and other factors that may cause market trends, industry results or Quintiles' actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Any statements contained on this site or in its related links that are not statements of historical fact are forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "should," "targets," "will" and the negative thereof and similar words and expressions are intended to identify forward-looking statements. These statements are subject to risks, uncertainties and assumptions and are imprecise by their very nature. For more information regarding these risks as they may affect Quintiles, please see the risk factors identified in Quintiles' filings with the Securities and Exchange Commission, which are available in the Investors Relations section of Quintiles' website at www.quintiles.com. Unless legally required, Quintiles assumes no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information.